2016MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.22(4):935-47[DOI] 10.1158/1078-0432.CCR-15-0534.[PMID] 26482043.